This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Our recent Q1 2025 scientific webinar brought together industry veterans Dr. Chris Waller and Dr. Dimitris Agrafiotis to discuss the current state and future directions of drug discovery informatics in large pharmaceutical organizations led by CDD's Founder and CEO, Dr. Barry Bunin.
We recently hosted an insightful webinar featuring the team from Congruence Therapeutics , who shared how they're using CDD Vault alongside their proprietary systems to manage complex drug discovery data.
In a recent webinar, Janice Darlington from Collaborative Drug Discovery (CDD) with Tamsin Mansley from Optibrium discussed the importance of collaboration in drug discovery and showcased how their software platforms, CDD Vault and StarDrop , can enhance collaborative efforts.
When I last wrote about AI on this blog three years ago, I spoke of it being a tool with the potential to transform scientific discovery, but the application I described was primarily theoretical. My message was that AI-enabled drug discovery was comingsomeday. Fast forward to 2025, and that someday is now.
Drug Discovery Industry Roundup with Barry Bunin — October 3, 2023 The New York Times coverage of the Nobel Prize in Physiology or Medicine being awarded.
The Current Situation with Falls In 2022 falls from elevation represented approximately 81% of all fatal and 20% of all nonfatal slips, trips, and falls for all industry workers (BLS 2023a, BLS 2023b). Many of these falls occurred in the construction industry, and significantly impact construction employers, workers, and their families.
Chemical registration is the most critical part of your discovery engine. If you are working without a chemical registration system (or avoiding your unwieldy legacy solution), you may be missing the full value of your data – wasting time and money.
Unlock the Secrets to a Successful Generic Drug Launch Are you a pharmaceutical executive looking to bring a generic version of a popular medication to market? Or perhaps you're a healthcare professional interested in understanding the intricacies of generic drug launches? So, what makes a generic drug launch successful?
Mastering the Art of Drug Patent Portfolio Management As a pharmaceutical professional, you know how crucial it is to navigate the complex landscape of drug patents. In our latest blog post, we dive into the best practices for drug patent portfolio management. But what does it take to excel in this field?
Valentine We recently blogged about a new December 2024 draft guidance about accelerated approval (the December 2024 draft guidance). This blog post focuses on interpreting these new authorities with respect to timely conduct of confirmatory trials. Tobolowsky & Charles G. Raver & James E.
Within this complex milieu, the interaction between stromal and tumor cellsoften referred to as stromal-tumor crosstalkplays a pivotal role in mediating drug resistance. Understanding and leveraging this variability through advanced models like co-culture systems is critical for developing effective, type-specific therapies.
With the explosion of advancements in AI and its growing impact on industries worldwide, including drug discovery, our team was eager to hear Aidan’s unique technical perspective on building and scaling a cutting-edge AI company, the top trends driving AI innovation, and the challenges and opportunities that lie ahead.
Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. The rest of this blog will focus on the Clinical Trials Grants Program. By Sarah Wicks & James E. Valentine — The U.S. Relative to other areas of medicine (e.g.,
Plastics are neither safe nor as inexpensive as they seem? A Strategy to Attack Aggressive Brain Cancer. Is LSD providing relief for Anxiety? And more.
BRAIN at 10: A View from the National Institute on Drug Abuse mfleming Wed, 09/25/2024 - 19:31 Nora's Blog October 1, 2024 By Nora Volkow, MD, Director, and Rita Valentino, Ph.D., Director, Division of Neuroscience and Behavior, NIDA This blog was originally posted on the The BRAIN Blog.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content